Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage

被引:54
作者
Boerma, JT [1 ]
Stanecki, KA
Newell, ML
Luo, C
Beusenberg, M
Garnett, GP
Little, K
Calleja, JG
Crowley, S
Kim, JY
Zaniewski, E
Walker, N
Stover, J
Ghys, PD
机构
[1] World Hlth Org, CH-1211 Geneva 27, Switzerland
[2] Joint United Nat Programme HIV AIDS, Geneva, Switzerland
[3] UCL, Inst Child Hlth, London, England
[4] UNICEF, New York, NY USA
[5] Imperial Coll Sch Med, London, England
[6] Futures Grp Inc, Glastonbury, CT USA
关键词
antiretroviral therapy; highly active; HIV infections/epiderniology/drug therapy; data collection/methods; needs assessment; trimethoprim-sulfamethoxazole combination; developing countries;
D O I
10.2471/BLT.05.025189
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This paper reviews the data sources and methods used to estimate the number of people on, and coverage of, antiretroviral therapy (ART) programmes in low- and middle-income countries and to monitor the progress towards the "3 by 5" target set by WHO and UNAIDS. We include a review of the data sources used to estimate the coverage of ART programmes as well as the efforts made to avoid double counting and over-reporting. The methods used to estimate the number of people in need of ART are described and expanded with estimates of treatment needs for children, both for ART and for cotrimoxazole prophylaxis. An estimated 6.5 million people were in need of treatment in low- and middle-income countries by the end of 2004, including 660 000 children under age 15 years. The mid-2005 estimate of 970 000 people receiving ART in low- and middle-income countries (with an uncertainty range 840 000-1 100 000) corresponds to a coverage of 15% of people in need of treatment.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 20 条
[1]  
Artzrouni M, 2002, AIDS, V16, pW1
[2]  
BATE R, SLIPPERY AIDS STAT L
[3]   A PROSPECTIVE-STUDY OF INFANTS BORN TO WOMEN SEROPOSITIVE FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 [J].
BLANCHE, S ;
ROUZIOUX, C ;
MOSCATO, MLG ;
VEBER, F ;
MAYAUX, MJ ;
JACOMET, C ;
TRICOIRE, J ;
DEVILLE, A ;
VIAL, M ;
FIRTION, G ;
DECREPY, A ;
DOUARD, D ;
ROBIN, M ;
COURPOTIN, C ;
CIRARUVIGNERON, N ;
LEDEIST, F ;
GRISCELLI, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (25) :1643-1648
[4]   Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controled trial [J].
Chintu, C ;
Bhat, GJ ;
Walker, AS ;
Mulenga, V ;
Sinyinza, F ;
Lishimpi, K ;
Farrelly, L ;
Kaganson, N ;
Zumla, A ;
Gillespie, SH ;
Nunn, AJ ;
Gibb, DM .
LANCET, 2004, 364 (9448) :1865-1871
[5]  
DABIS F, 2005, P 12 C RETR OPP INF
[6]   Highly active antiretroviral therapies among HIV-1 infected children in Abidjan, Cote d'Ivoire [J].
Fassinou, P ;
Elenga, N ;
Rouet, F ;
Laguide, R ;
Kouakoussui, KA ;
Timite, M ;
Blanche, S ;
Msellati, P .
AIDS, 2004, 18 (14) :1905-1913
[7]   The UNAIDS Estimation and Projection Package: a software package to estimate and project national HIV epidemics [J].
Ghys, PD ;
Brown, T ;
Grassly, NC ;
Garnett, G ;
Stanecki, KA ;
Stover, J ;
Walker, N .
SEXUALLY TRANSMITTED INFECTIONS, 2004, 80 :i5-i9
[8]  
GRASSLY NC, 2005, SEX TRANSM INFECT, V81, P279
[9]   Changing patterns of mortality across Europe in patients infected with HIV-1 [J].
Mocroft, A ;
Vella, S ;
Benfield, TL ;
Chiesi, A ;
Miller, V ;
Gargalianos, P ;
Monforte, AD ;
Yust, I ;
Bruun, JN ;
Phillips, AN ;
Lundgren, JD .
LANCET, 1998, 352 (9142) :1725-1730
[10]   HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? [J].
Morgan, D ;
Mahe, C ;
Mayanja, B ;
Okongo, JM ;
Lubega, R ;
Whitworth, JAG .
AIDS, 2002, 16 (04) :597-603